Alkermes plc (ALKS) has risen sharply, recording gains of 4.23% in the past 4 weeks. However, the stock has corrected -5.14% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 4.8% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 2.2% and the 50-Day Moving Average is 1.1%.The 200 Day SMA reached 4.75%
Alkermes plc (NASDAQ:ALKS): After opening at $47.16, the stock dipped to an intraday low of $46.11 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $47.2174 and the buying power remained strong till the end. The stock closed at $47.03 for the day, a gain of 0.69% for the day session. The total traded volume was 701,140. The stocks close on the previous trading day was $47.03.
Alkermes plc (ALKS) : The highest level Alkermes plc (ALKS) is projected to reach is $66 for the short term and the lowest estimate is at $60. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $62.67 and the possibility the share price can swing is $3.06.
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Companys main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.